<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190047</url>
  </required_header>
  <id_info>
    <org_study_id>Ptcl-01213</org_study_id>
    <nct_id>NCT00190047</nct_id>
  </id_info>
  <brief_title>Effects Of DP-b99 On Neurological Function In Subjects With Acute Ischemic Hemispheric Stroke</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Study To Evaluate The Effects Of DP-b99 On Neurologic Function And Disability In Subjects With Acute Ischemic Hemispheric Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>D-Pharm Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>D-Pharm Ltd.</source>
  <brief_summary>
    <textblock>
      This study will examine if DP-b99 can improve neurological function (for example strength and
      coordination) in the 3 months after an acute stroke
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include a Screening/Baseline Period, a Treatment Period, and a Post-treatment
      Follow-up Period. During the Screening Period, subjects will be selected for the study on the
      basis of inclusion and exclusion criteria (see below). A screening computed tomography scan
      to exclude brain bleeding will be performed. The patient's informed consent will be obtained.
      The patient will be randomly allocated to DP-b99 or placebo. Immediately after this
      randomization and baseline assessments (lab tests and ECG), subjects will be given a 2-hour
      intra-venous infusion of DP-b99 or placebo. Additional 3 such infusions will then be given
      daily to a total of 4 consecutive treatment days, which make up the &quot;Treatment Period&quot;.
      Throughout the 4-day Treatment Period the treatment's safety and the National Institutes of
      Health Stroke Scale (NIHSS) score will be evaluated daily. (The NIHSS assesses certain
      abilities of the patient, e.g. strength, speech, vision and coordination). If their condition
      requires, patients may have to stay in hospital more than these 4 days, regardless of their
      participation in the study.Subjects will be further assessed for NIHSS score changes and
      safety (lab tests and ECG) during the Post-treatment Follow-up Period, with data collected 30
      and 90 days after the stroke. Other outcome scales (Barthel Index and Modified Rankin Scale)
      will be also used in the Day 30 and Day 90 visits
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date>October 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the National Institutes of Health Stroke Scale (NIHSS) score from baseline to Day 90</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability Neurological recovery and function</measure>
  </secondary_outcome>
  <enrollment>150</enrollment>
  <condition>Brain Ischemia</condition>
  <condition>Stroke</condition>
  <condition>Cerebrovascular Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DP-b99</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients that may enter the study:

          -  Patients with ischemic stroke, (that is, stroke that results from a blockage of blood
             flow to part of the brain), which is accompanied by language dysfunction (e.g.
             inability to understand speech), visual field defect or inattention to one side of the
             body or the space around the patient.

          -  Patients in whom the study treatment can start no less than 1 and not more than 9
             hours after the stroke's onset

          -  Patients with moderate-severe degree of neurological deficit in the 9 hours after
             stroke onset (defined as NIHSS score of 7 to 20

          -  Patients that can understand the requirements of the study and are willing to provide
             written informed consent (If the subject is incapacitated, informed consent will be
             sought from a legally acceptable representative.)

        Patients that cannot participate:

          -  Patients with a brain (intracerebral or subarachnoid) hemorrhage per screening
             computed tomography scan candidates for thrombolytic therapy for the current stroke
             patients having a mental impairment that renders them incapable to understand the
             study's requirements patients with other diseases that in the investigator's opinion
             may lead, independently of the current stroke, to further deterioration in the
             subject's neurological status during the trial period, or may confuse the evaluation
             of the present stroke

          -  Patients likely to undergo a procedure involving cardiopulmonary bypass during the
             study period

          -  Patients with medical conditions that may not enable them to complete the study (e.g
             life-threatening diseases,)

          -  Patients whose condition improves already during the screening period

          -  Patients who already have functional limitations before the present study
             (retrospective Modified Rankin Scale score of &gt;3)

          -  Patients who suffered a stroke within the past 90 days that seems to have been in the
             same brain region as the current acute stroke

          -  Patients with severe hypertension (systolic BP &gt;210 mm Hg or diastolic BP &gt;120 mm Hg)
             or hypotension (systolic BP &lt;90 mm Hg), Patients with significant history of renal or
             liver disease(s) (serum creatinine of &gt; 2.0 mg/dL; alanine aminotransferase, aspartate
             aminotransferase, or gamma-glutamyl transferase values of &gt; threefold the upper normal
             limit)

          -  Patients with a platelet count of &lt;100,000/mm3

          -  Female patients of childbearing potential who are not using adequate and effective
             birth control measures or who are pregnant or lactating (the screening evaluation of
             female subjects of childbearing potential will include a serum pregnancy test.)

          -  Patients who are users of addictive agents, or alcoholics

          -  Patients who have received an investigational drug within the 90 days before the
             present stroke or such that are past recipients of DP-b99
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilad Rosenberg, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>D-Pharm Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurologische Klink GmbH der Rhoen-Klinikum AG</name>
      <address>
        <city>Bad Neustadt / Saale</city>
        <zip>97616</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin / Campus Charité Mitte, Klinik und Poliklinik für Neurologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Essen Klinik und Poliklinik für Neurologie</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik Abteilung für Neurologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Neurologie Klinikum der Universität zu Köln</name>
      <address>
        <city>Köln</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig Klinik und Poliklinik für Neurologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke-Universität Magdeburg Medizinische Fakultät, Klinik für Neurologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg-Universität Mainz Neurologische Klinik</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum 1 Minden Neurologische Klinik</name>
      <address>
        <city>Minden</city>
        <zip>32427</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Krankenhaus München-Harlaching Abteilung für Neurologie</name>
      <address>
        <city>München-Harlaching</city>
        <zip>81545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik und Poliklinik Technische Universität München Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Krankenhaus München-Bogenhausen Abteilung für Neurologie und Klinische</name>
      <address>
        <city>München</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster Klinik und Poliklinik für Neurologie</name>
      <address>
        <city>Münster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Osnabrück Abteilung Neurologie</name>
      <address>
        <city>Osnabrück</city>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Recklinghausen Klinik für Neurologie und Klinische Neurophysiologie</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm Abteilung für Neurologie im RKU</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Zentrum Kreis Aachen gGmbH Klinik für Neurologie</name>
      <address>
        <city>Würselen-Bardenberg</city>
        <zip>52146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>58220</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Kerem Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Oral Session on Acute stroke: treatment concepts, presented on Thursday, 31 May 2007 at the XVI. European Stroke Conference, Glasgow, United Kingdom, 29 May - 1 June 2007. The abstract can be found at: http://www.esc-archive.eu/glasgow07/gla_so10_1.asp</citation>
  </results_reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>November 22, 2007</last_update_submitted>
  <last_update_submitted_qc>November 22, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2007</last_update_posted>
  <keyword>Cerebral Ischemia</keyword>
  <keyword>Ischemic Brain Injury</keyword>
  <keyword>Brain Infarction</keyword>
  <keyword>Brain Ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

